S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

LaserAway Marks Two Decades of Growth with 230th Clinic Opening

Two decades after launching a single clinic on Sunset Boulevard, LaserAway has reached a milestone with its 230th location. The new Washington, D.C. site at 1427 P St. NW underscores the company’s sustained expansion, having maintained an uninterrupted growth trajectory since its 2006 founding in West Hollywood.

LaserAway Marks Two Decades of Growth with 230th Clinic Opening
Photo: Bio & News

The company’s expansion strategy relies on a privately owned model, eschewing franchising to maintain centralized control over its 230 sites across 36 states. Founded by Dr. Roy Winston alongside Scott, Brock, and Todd Heckmann, the firm positions itself as a bridge between specialized medical care and consumer convenience. CEO Scott Heckmann noted that the initial vision focused on democratizing access to aesthetic treatments that were previously limited to a narrow demographic.

Clinical operations are overseen by Chief Medical Officer Dr. Will Kirby, who manages a medical board of over 25 board-certified dermatologists. The staff, which includes 700 nurses, performs services ranging from laser hair removal and skin rejuvenation to body contouring procedures like CoolSculpting and Thermage. By requiring all treatments to be administered by licensed professionals—including nurse practitioners and physician assistants—the brand aims to differentiate its medical-grade service from standard retail aesthetics.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!